Earlier this month, the National Institute for Health and Care Excellence (NICE), which stipulates which medical interventions are covered by England and Wales’ National Health Service (NHS), issued a statement that effectively brings Janssen’s ambitions to have its esketamine nasal spray (Spravato) product for treatment-resistant depression (TRD) reimbursed by the NHS in the UK’s most populous countries to a close.
After a half-decade of back-and-forth, the agency has again stood by its recommendation that Spravato not be covered by the state-backed health system. That original recommendation, delivered in 2020, revealed that the public body was not convinced by the product’s clinical data or cost-effectiveness.
The remit of this latest review, then, was “to consider whether any evidence presented would change the current recommendation”, NICE explained. It concluded that it would not.
Contents
- A Half-Decade Battle Bears No Fruit for Janssen
- Janssen Hoped Head-to-Head Quietiapine Study Might Quiet NICE’s Concerns
- Implications for Psychedelic Therapies
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
